Payment overview · 2025
General Payments
$280.29
18 reported records · 6 companies
Healthcare provider profile · identity verified
Mandev Guram, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · IRMO, SC · NPI 1922489285
Verified facts
What the public records show
CMS Open Payments records show Mandev Guram, M.D. received $280.29 in general payments during 2025 across 18 reported records.
Abbott Laboratories accounted for 42.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $120.17 | 42.9% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $45.21 | 16.1% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$44.65 | 15.9% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $32.48 | 11.6% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $21.93 | 7.8% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $15.85 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $280.29 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $45.21 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $45.21 | 3 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $44.65 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $32.48 | 2 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $15.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 439 | 142 |
| Atorvastatin Calcium | Atorvastatin Calcium | 404 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 343 | 101 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 315 | 99 |
| Losartan Potassium | Losartan Potassium | 304 | 88 |
| Omeprazole | Omeprazole | 280 | 98 |
| Lisinopril | Lisinopril | 263 | 83 |
| Alprazolam | Alprazolam | 227 | 59 |
| Gabapentin | Gabapentin | 212 | 81 |
| Ozempic | Semaglutide | 209 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 205 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 202 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 185 | 65 |
| Trazodone Hcl | Trazodone Hcl | 181 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 177 | 56 |
| Zolpidem Tartrate | Zolpidem Tartrate | 174 | 46 |
| Lorazepam | Lorazepam | 166 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 51 |
| Sertraline Hcl | Sertraline Hcl | 158 | 53 |
| Eliquis | Apixaban | 154 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 153 | 48 |
| Clonazepam | Clonazepam | 152 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 152 | 46 |
| Furosemide | Furosemide | 148 | 54 |
| Famotidine | Famotidine | 137 | 42 |
| Montelukast Sodium | Montelukast Sodium | 131 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 34 |
| Mounjaro | Tirzepatide | 115 | 19 |
| Meloxicam | Meloxicam | 114 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 46 |
| Metformin Hcl | Metformin Hcl | 105 | 34 |
| Simvastatin | Simvastatin | 104 | 32 |
| Glipizide Er | Glipizide | 92 | 25 |
| Carvedilol | Carvedilol | 91 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 87 | 23 |
| Spironolactone | Spironolactone | 85 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 80 | 67 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 76 | 20 |
| Mirtazapine | Mirtazapine | 74 | 18 |
| Tramadol Hcl | Tramadol Hcl | 74 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 72 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 69 | 29 |
| Allopurinol | Allopurinol | 62 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 23 |
| Jardiance | Empagliflozin | 61 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 61 | 14 |
| Potassium Chloride | Potassium Chloride | 60 | 23 |
| Buspirone Hcl | Buspirone Hcl | 59 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 42 |
| Azithromycin | Azithromycin | 51 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 27 |
| Pregabalin | Pregabalin | 49 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | 14 |
| Atenolol | Atenolol | 47 | 16 |
| Diazepam | Diazepam | 47 | 19 |
| Ondansetron Odt | Ondansetron | 47 | 15 |
| Baclofen | Baclofen | 45 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 45 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 14 |
| Glipizide | Glipizide | 44 | 19 |
| Fluconazole | Fluconazole | 43 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 42 | suppressed |
| Trulicity | Dulaglutide | 41 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 36 |
| Prednisone | Prednisone | 40 | 27 |
| Bupropion Xl | Bupropion Hcl | 39 | 18 |
| Finasteride | Finasteride | 38 | 12 |
| Xarelto | Rivaroxaban | 38 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | 16 |
| Valsartan | Valsartan | 36 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | 16 |
| Benazepril Hcl | Benazepril Hcl | 33 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | 12 |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Celecoxib | Celecoxib | 29 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | 12 |
| Irbesartan | Irbesartan | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 26 |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 21 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | 11 |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Estradiol | Estradiol | 27 | 13 |
| Sucralfate | Sucralfate | 27 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 16 |
| Latanoprost | Latanoprost | 25 | suppressed |
| Premarin | Estrogens, Conjugated | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Onzetra Xsail | Sumatriptan Succinate | 12 | suppressed |
| Osphena | Ospemifene | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Sulindac | Sulindac | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $280.29 · 18 records | Abbott Laboratories | CLOTTRIEVER BOLD CATHETER, GLYCATE, INTELLIS ADAPTIVESTIM, Korlym, QULIPTA, RELTONE 200 MG, RELTONE 400 MG, UBRELVY | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error